NFAT5 governs cellular plasticity-driven resistance to KRAS-targeted therapy in pancreatic cancer
Journal of Experimental Medicine · 04.11.2024 · 221 (11)
DOI: 10.1084/jem.20240766 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 21.10.2024. Verfasst von Daiyong Deng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers University New Jersey Medical School, Newark, NJ, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: Rutgers Cancer Institute of New Jersey, Rutgers New Jersey Medical School, NIH HHS.
Abstract (Originalsprache)
Resistance to KRAS therapy in pancreatic ductal adenocarcinoma (PDAC) involves cellular plasticity, particularly the epithelial-to-mesenchymal transition (EMT), which poses challenges for effective targeting. Chronic pancreatitis, a known risk factor for PDAC, elevates TGFβ levels in the tumor microenvironment (TME), promoting resistance to KRAS therapy. Mechanistically, TGFβ induces the formation of a novel protein complex composed of SMAD3, SMAD4, and the nuclear factor NFAT5, triggering EMT and resistance by activating key mediators such as S100A4. Inhibiting NFAT5 attenuates pancreatitis-induced resistance to KRAS inhibition and extends mouse survival. Additionally, TGFβ stimulates PDAC cells to secrete CCL2, recruiting macrophages that contribute to KRAS bypass through paracrine S100A4. Our findings elucidate the role of TGFβ signaling in EMT-associated KRAS therapy resistance and identify NFAT5 as a druggable target. Targeting NFAT5 could disrupt this regulatory network, offering a potential avenue for preventing resistance in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers University New Jersey Medical School, Newark, NJ, USA.
- Center for Cell Signaling, Rutgers University New Jersey Medical School , Newark, NJ, USA.
- Center for Immunity and Inflammation, Rutgers University New Jersey Medical School , Newark, NJ, USA.
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Rutgers Cancer Institute of New Jersey, Rutgers University , New Brunswick, NJ, USA.
ORCID-Profile: Daiyong Deng, Habeebunnisa Begum, Tong Liu, Jiangyan Zhang, Qiang Zhang, Ting-Yu Chu, Hong Li, Alexander Lemenze, Mainul Hoque, Patricia Soteropoulos, Pingping Hou
Förderung
- Rutgers Cancer Institute of New Jersey
- Rutgers New Jersey Medical School
- NIH HHS
- NCI NIH HHS
- Lustgarten Foundation
- NINDS NIH HHS
- National Institutes of Health
Zitieren
APA
Deng, D., Begum, H., Liu, T., Zhang, J., Zhang, Q., Chu, T. Y., Li, H., Lemenze, A., Hoque, M., Soteropoulos, P., & Hou, P. (2024). NFAT5 governs cellular plasticity-driven resistance to KRAS-targeted therapy in pancreatic cancer. Journal of Experimental Medicine, 221(11). https://doi.org/10.1084/jem.20240766
Vancouver
Deng D, Begum H, Liu T, Zhang J, Zhang Q, Chu TY, et al. NFAT5 governs cellular plasticity-driven resistance to KRAS-targeted therapy in pancreatic cancer. Journal of Experimental Medicine. 2024;221(11). doi:10.1084/jem.20240766
BibTeX
@article{Deng2024,
author = {Deng, Daiyong and Begum, Habeebunnisa and Liu, Tong and Zhang, Jiangyan and Zhang, Qiang and Chu, Ting-Yu and Li, Hong and Lemenze, Alexander and Hoque, Mainul and Soteropoulos, Patricia and Hou, Pingping},
title = {NFAT5 governs cellular plasticity-driven resistance to KRAS-targeted therapy in pancreatic cancer},
journal = {Journal of Experimental Medicine},
year = {2024},
volume = {221},
number = {11},
doi = {10.1084/jem.20240766}
}
EUVIMED